Pharma Industry staring at 30-40 bps hit on updated NLEM
The updated national list of essential medicines (NLEM) announced by the government could potentially shave off between 30 and 40 basis points (bps) of the Indian pharmaceutical market (IPM) as per existing price control methodology, pharma executives and analysts told ET. The IPM size for the year ended August 31, 2022 was around ₹1,73,872 crore.
The government in its updated list added 34 new drugs, including some top-selling medications such as amikacin, cefuroxime, insulin glargine, itraconazole, mupirocin and teneligliptin with each having annual sales of more than ₹300 crore. The drugs under NLEM list will be subjected to price control, and their annual price hikes are linked to wholesale price index (WPI) inflation. “Definitely it will have an impact one eve ..
Read more at: ECONOMIC TIMES
Leave a Reply